Visgeneer (4197) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Visgeneer (4197) has a cash flow conversion efficiency ratio of -0.060x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-11.86 Million ≈ $-373.78K USD) by net assets (NT$197.35 Million ≈ $6.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4197 equity financing ratio to measure how much of total assets are equity-financed.
Visgeneer - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Visgeneer's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 4197 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Visgeneer Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Visgeneer ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nyrstar NV
BR:NYR
|
0.000x |
|
HYDROGEN UTOPIA INT.-001
F:D60
|
N/A |
|
Scandinavian ChemoTech AB Series B
ST:CMOTEC-B
|
-0.698x |
|
EA Holdings Bhd
KLSE:0154
|
-0.070x |
|
Intanwijaya Internasional Tbk
JK:INCI
|
0.079x |
|
Synaptogenix Inc
NASDAQ:SNPX
|
-0.042x |
|
AB Effectenbeteiligungen AG
STU:JPH
|
N/A |
|
Bitros Holding S.A
AT:MPITR
|
0.006x |
Annual Cash Flow Conversion Efficiency for Visgeneer (2012–2025)
The table below shows the annual cash flow conversion efficiency of Visgeneer from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Visgeneer market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$199.09 Million ≈ $6.27 Million |
NT$13.37 Million ≈ $421.10K |
0.067x | +227.39% |
| 2024-12-31 | NT$193.84 Million ≈ $6.11 Million |
NT$-10.22 Million ≈ $-321.86K |
-0.053x | -184.52% |
| 2023-12-31 | NT$211.57 Million ≈ $6.67 Million |
NT$13.19 Million ≈ $415.62K |
0.062x | -66.90% |
| 2022-12-31 | NT$231.16 Million ≈ $7.28 Million |
NT$43.55 Million ≈ $1.37 Million |
0.188x | +234.16% |
| 2021-12-31 | NT$218.81 Million ≈ $6.89 Million |
NT$12.34 Million ≈ $388.65K |
0.056x | +62.41% |
| 2020-12-31 | NT$218.00 Million ≈ $6.87 Million |
NT$7.57 Million ≈ $238.40K |
0.035x | +164.63% |
| 2019-12-31 | NT$217.39 Million ≈ $6.85 Million |
NT$-11.68 Million ≈ $-367.83K |
-0.054x | -415.42% |
| 2018-12-31 | NT$249.15 Million ≈ $7.85 Million |
NT$-2.60 Million ≈ $-81.79K |
-0.010x | +87.57% |
| 2017-12-31 | NT$281.04 Million ≈ $8.85 Million |
NT$-23.55 Million ≈ $-742.02K |
-0.084x | -182.83% |
| 2016-12-31 | NT$311.69 Million ≈ $9.82 Million |
NT$31.54 Million ≈ $993.59K |
0.101x | +0.27% |
| 2015-12-31 | NT$315.69 Million ≈ $9.95 Million |
NT$31.86 Million ≈ $1.00 Million |
0.101x | +198.67% |
| 2014-12-31 | NT$309.25 Million ≈ $9.74 Million |
NT$10.45 Million ≈ $329.17K |
0.034x | -78.76% |
| 2013-12-31 | NT$285.60 Million ≈ $9.00 Million |
NT$45.42 Million ≈ $1.43 Million |
0.159x | -36.02% |
| 2012-12-31 | NT$250.23 Million ≈ $7.88 Million |
NT$62.20 Million ≈ $1.96 Million |
0.249x | -- |
About Visgeneer
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cr… Read more